Ocugen, Inc. (NASDAQ: OCGN) Investor Alert: Lawsuit alleges Securities Laws Violations

A lawsuit was filed in the U.S. District Court for the Eastern District of Pennsylvania by an investor who bought shares of Ocugen, Inc. (NASDAQ: OCGN) alleging that the company violated federal securities laws in relation to some allegedly false and misleading statements made between May 8, 2020 and April 1, 2024.

You have specific options, and for some investors, there are tight deadlines, if you bought a sizable quantity of Ocugen, Inc. (NASDAQ: OCGN) shares between May 8, 2020 and April 1, 2024, and/or if you bought any NASDAQ: OCGN shares before May 2020 and you still own any of those shares. June 10, 2024 is the deadline. NASDAQ: Investors in OCGN should get in touch with the Shareholders Foundation by phone at +1(858) 779-1554 or via email at [email protected].

Ocugen, Inc., a clinical-stage biopharmaceutical business situated in Malvern, PA, is focused on creating gene treatments to treat blindness-causing conditions.

Ocugen submitted their Form 10-Q quarterly report for the period ending March 31, 2020, to the SEC on May 8, 2020.

Ocugen submitted their Form 10-Q quarterly report for the quarter ended June 30, 2020, to the SEC on August 14, 2020.

Ocugen submitted their Form 10-Q quarterly report for the quarter ended September 30, 2020, to the SEC on November 6, 2020.

Ocugen submitted its 2020 Annual Report on Form 10-K, covering the year that concluded on December 31, 2020, to the SEC on March 19, 2021.

Ocugen submitted their Form 10-Q quarterly report to the SEC on May 7, 2021, covering the period ending on March 31, 2021.

Ocugen submitted its Form 10-Q quarterly report for the quarter that concluded on June 30, 2021, to the SEC on August 6, 2021.

Ocugen submitted its Form 10-Q quarterly report to the SEC for the period ending September 30, 2021, on November 9, 2021.

Ocugen submitted its Form 10-K annual report for the year ended December 31, 2021, to the SEC on February 28, 2022.

Ocugen submitted its Form 10-Q quarterly report for the period ending March 31, 2022, to the SEC on May 6, 2022.

Ocugen submitted its Form 10-Q quarterly report for the quarter ended June 30, 2022, to the SEC on August 5, 2022.

Ocugen submitted its Form 10-Q quarterly report for the quarter ended September 30, 2022, to the SEC on November 8, 2022.

Ocugen submitted its Form 10-K annual report to the SEC for the fiscal year that concluded on December 31, 2022, on February 28, 2023.

Ocugen submitted its Form 10-Q quarterly report for the period ending March 31, 2023, to the SEC on May 5, 2023.

Ocugen submitted its Form 10-Q quarterly report for the quarter ended June 30, 2023, to the SEC on August 21, 2023.

Ocugen submitted their Form 10-Q quarterly report for the quarter ended September 30, 2023, to the SEC on November 9, 2023.

Following the market close on April 1, 2024, Ocugen, Inc. filed a current report on Form 8-K with the SEC. According to the report, the previously published unaudited interim condensed consolidated financial statements for the first three quarters of those years, as well as the previously published audited consolidated financial statements for each fiscal year beginning on January 1, 2020, were found to contain significant misstated information. The audit committee of the board of directors reached this conclusion after consulting with EY and acting on management’s recommendation. They should therefore no longer be trusted. The accompanying investor presentations, earnings announcements, and other communications that included the financial statements’ description were also covered by this conclusion.Furthermore, the business filed a statement on Form 12b-25 on April 1, 2024, stating that it was unable to timely file the Form 10-K. The requirement for further time to fix the previously noted mistakes and compile restated financial accounts was the cause of this delay. There is no guarantee that the corporation will be able to achieve its April 16, 2024, deadline for filing the 2023 Form 10-K.

Ocugen, Inc. (NASDAQ: OCGN) saw a decrease in share price from $2.105 on March 25, 2024, to $1.34 on April 02, 2024.

In the complaint, the plaintiff claims that the defendants broke federal securities laws while selling common shares of Ocugen, Inc. (NASDAQ: OCGN) to buyers between May 8, 2020 and April 1, 2024. In more detail, the plaintiff alleges that the defendants made materially false and/or misleading statements between May 8, 2020 and April 1, 2024, and/or neglected to disclose that Ocugen, Inc.’s financial statements from May 8, 2020 to the present were materially misstated, that Ocugen, Inc. lacked adequate internal controls, and that, as a result, the defendants’ statements about its operations, business, and prospects were false and/or without a reasonable basis at all times.

Shareholders Foundation should be contacted by those who bought shares in Ocugen, Inc. (NASDAQ: OCGN), as they have certain choices.

Get in touch with Investors Foundation, Inc.Michael Daniels: +1-(858)-779-1554; 3111 Camino Del Rio North, Suite 42392108, San Diego(858)[email protected] is the fax number.

About The Shareholders Foundation, Inc.: We are a professional portfolio monitoring and settlement claim filing service that keeps investors informed about securities class actions, settlements, judgments, and other legal news pertaining to the stock and financial markets. We also conduct research on shareholder issues. With a vast network of contacts, Shareholders Foundation, Inc. provides support, guidance, and aid to each and every shareholder. It is not a law firm, The Shareholders Foundation, Inc. The Shareholders Foundation is not involved in the filed, reached, or settled cases, investigations, or settlements mentioned. The public is offered this information as a service. It should not be relied upon and is not meant to be legal advice.